The oligometastatic paradigm and the role of radiotherapy

Article Oncology

Development of a Prognostic Model for Overall Survival in Patients With Extracranial Oligometastatic Disease Treated With Stereotactic Body Radiation Therapy

Hanbo Chen et al.

Summary: A prognostic model for overall survival in patients with extracranial oligometastatic disease treated with stereotactic body radiation therapy (SBRT) has been developed and validated.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2022)

添加到收藏夹

Editorial Material Urology & Nephrology

Substituting SABR for systemic therapy in oligometastatic renal cell carcinoma - buying time or time to change?

Shankar Siva et al.

Summary: In this first of its kind trial for oligometastatic renal cell carcinoma, stereotactic ablative body radiotherapy was successfully delivered instead of systemic therapy. This strategy should be considered for selected patients with oligometastatic RCC.

NATURE REVIEWS UROLOGY (2022)

添加到收藏夹

Article Oncology

A multicenter LArge retrospectIve daTabase on the personalization of stereotactic ABlative radiotherapy use in lung metastases from colon-rectal cancer: The LaIT-SABR study

L. Nicosia et al.

Summary: This study investigated the efficacy and predictive factors of SABR in the treatment of lung colorectal metastases using a large multicenter retrospective database. The results showed that SABR could delay the progression to polymetastatic disease (PMD) and provide a relatively long disease-free period in selected cases. Furthermore, predictive factors were identified for treatment personalization.

RADIOTHERAPY AND ONCOLOGY (2022)

添加到收藏夹

Review Oncology

PSMA PET in Imaging Prostate Cancer

Ioannis Tsechelidis et al.

Summary: PSMA PET, the latest nuclear medicine development, is regarded as the most promising tool for the diagnosis and treatment of prostate malignancy. However, there is still debate and ongoing research regarding its utility and position in guidelines, requiring further studies and trials for clarification.

FRONTIERS IN ONCOLOGY (2022)

添加到收藏夹

Article Oncology

Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

Hyuna Sung et al.

Summary: The global cancer burden in 2020 saw an estimated 19.3 million new cancer cases and almost 10.0 million cancer deaths. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer, while lung cancer remained the leading cause of cancer death. These trends are expected to rise in 2040, with transitioning countries experiencing a larger increase compared to transitioned countries due to demographic changes and risk factors associated with globalization and a growing economy. Efforts to improve cancer prevention measures and provision of cancer care in transitioning countries will be crucial for global cancer control.

CA-A CANCER JOURNAL FOR CLINICIANS (2021)

添加到收藏夹

Article Oncology